Can anti-Mullerian hormone (AMH) predict the outcome of intrauterine insemination with controlled ovarian stimulation?
OBJECTIVE
To assess whether the levels of anti-Mullerian hormone (AMH) are related to outcome of intrauterine insemination (IUI) in patients treated with gonadotropins.


METHODS
A total of 195 patients underwent controlled ovarian stimulation (COS) with recombinant follicle stimulating hormone (rFSH) (50-150 IU/d). All patients were submitted upto three cycles of IUI.


RESULTS
Primary outcome was the ability of AMH levels to predict clinical pregnancy at first attempt and the cumulative clinical pregnancy probability of upto three IUI cycles. Secondary outcomes were the relation of AMH, LH, FSH, BMI, age, parity and basic estradiol levels with each other and the outcome of IUI.


RESULTS
The area under the receiver operating characteristic (ROC) curve in predicting clinical pregnancy for AMH at first attempt was 0.53 and for cumulative clinical pregnancy was 0.76. AMH levels were positively correlated with clinical pregnancy rate at first attempt and with cumulative clinical pregnancy rate, but negatively correlated with patient's age and FSH levels. Patient's FSH, LH levels were negatively correlated with cumulative clinical pregnancy rate.


CONCLUSIONS
AMH levels seem to have a positive correlation and patient's age and LH levels had a negative correlation with the outcome of IUI and COS with gonadotropins. AMH concentration was significantly higher and LH was significantly lower in patients with a clinical pregnancy after three cycles of IUI treatment compared with those who did not achieve pregnancy.
a 2nd Department of Obstetrics and Gynecology , Aretaieion Hospital, University of Athens , Athens , Greece.
Panagiotis
P
Bakas
a 2nd Department of Obstetrics and Gynecology , Aretaieion Hospital, University of Athens , Athens , Greece.
Ioannis
I
Boutas
a 2nd Department of Obstetrics and Gynecology , Aretaieion Hospital, University of Athens , Athens , Greece.
Maria
M
Creatsa
a 2nd Department of Obstetrics and Gynecology , Aretaieion Hospital, University of Athens , Athens , Greece.
Nicos
N
Vlahos
a 2nd Department of Obstetrics and Gynecology , Aretaieion Hospital, University of Athens , Athens , Greece.
Odysseas
O
Gregoriou
a 2nd Department of Obstetrics and Gynecology , Aretaieion Hospital, University of Athens , Athens , Greece.
George
G
Creatsas
a 2nd Department of Obstetrics and Gynecology , Aretaieion Hospital, University of Athens , Athens , Greece.
Dimitrios
D
Hassiakos
D000328:Adult; D054304:Anti-Mullerian Hormone / Q000097:blood*; D004958:Estradiol / Q000097:blood; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood / Q000627:therapeutic use; D006801:Humans; D007247:Infertility, Female / Q000097:blood / Q000628:therapy*; D007315:Insemination, Artificial; D007986:Luteinizing Hormone / Q000097:blood; D010062:Ovulation Induction; D011247:Pregnancy; D018873:Pregnancy Rate; D016896:Treatment Outcome
D004958:Estradiol; D054304:Anti-Mullerian Hormone; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone
Assisted reproductive technology; estrogens; infertility